Vaxart, Inc. (VXRT) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 241.97M; Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 241.97M | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-04-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 241.97M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-03-31 | 241.97M | (m) | (m) |
| 2025-12-31 | 240.63M | (m) | (m) |
| 2025-09-30 | 240.07M | (m) | (m) |
| 2025-06-30 | 228.92M | (m) | (m) |
| 2025-03-31 | 228.22M | (m) | (m) |
| 2024-12-31 | 227.95M | (m) | (m) |
| 2024-09-30 | 227.48M | (m) | (m) |
| 2024-06-30 | 227.44M | (m) | (m) |
| 2024-03-31 | 176.84M | (m) | (m) |
| 2023-12-31 | 173.86M | (m) | (m) |
| 2023-09-30 | 152.04M | (m) | (m) |
| 2023-06-30 | 151.97M | (m) | (m) |
| 2023-03-31 | 135.60M | (m) | (m) |
| 2022-12-31 | 135.56M | (m) | (m) |
| 2022-09-30 | 131.25M | (m) | (m) |
| 2022-06-30 | 126.51M | (m) | (m) |
| 2022-03-31 | 126.45M | (m) | (m) |
| 2021-09-30 | 125.50M | (m) | (m) |
| 2021-06-30 | 122.82M | (m) | (m) |
| 2021-03-31 | 122.27M | (m) | (m) |
| 2020-09-30 | 109.47M | (m) | (m) |
| 2020-06-30 | 109.20M | (m) | (m) |
| 2020-03-31 | 74.18M | (m) | (m) |
| 2019-09-30 | 47.72M | (m) | (m) |
| 2019-06-30 | 15.79M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |